Jagsonpal Q4 FY26: Growth returns, cash builds, and capital comes back to shareholders

Q4 FY26 revenue was INR 642 million, operating EBITDA (pre-ESOP) was INR 106 million, and PAT excluding exceptional items was INR 88 million.

FY26 revenue from operations was INR 2,872 million, operating EBITDA (pre-ESOP) was INR 609 million, and PAT excluding exceptional items was INR 446 million.

The company approved a buyback of up to 16 lakh equity shares at INR 250 per share with a total outlay of about INR 40 crore; promoters will not participate.

The board recommended a 200% dividend for FY26 including a 75% special dividend, amounting to INR 4 per equity share (FV INR 2) and total payout of about INR 26.2 crore, subject to shareholder approval.

Management reiterated an objective to grow revenue at 1.5 times the growth rate of the Indian Pharma Market (IPM) in FY27.

The company stated its core therapy focus includes Gynaecology, Orthopaedics, Dermatology, and Child-care (Pediatrics), with strong coverage of specialists in these areas.